NBIX vs OCUL Stock Comparison
NBIX currently leads OCUL in this stock comparison, with AIQ scores of 74 vs 38. The clearest difference is quality.
What is the main difference between NBIX and OCUL?
NBIX leads the current stock comparison as Neurocrine Biosciences, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Neurocrine Biosciences, Inc. vs Ocular Therapeutix, Inc.
NBIX leads
NBIX leads by 36 AIQ points, primarily on Quality and Value, and the lead has widened from 24 points over 30 sessions. Wall Street currently favors OCUL on target upside.
Stable: 5 of 6 evidence groups support NBIX, its lead is widening, and its current signal state is conflicted.
Neurocrine Biosciences, Inc.
Ocular Therapeutix, Inc.
The Algovestiq AIQ Score currently favors NBIX over OCUL, 74 versus 38 as of Nov 15, 2026. NBIX's advantage is driven primarily by stronger quality and value. NBIX also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors OCUL. 5 of 6 covered evidence groups favor NBIX today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. NBIX lead: Strengthening — the AIQ differential moved from 24 to 36 points over 30 sessions. NBIX leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.
Compare Neurocrine Biosciences, Inc. and Ocular Therapeutix, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare NBIX and OCUL against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality79 vs 42NBIX +37
- Value77 vs 41NBIX +36
- Momentum70 vs 34NBIX +36
- Risk Resilience69 vs 36NBIX +33
5 of 6 evidence groups favor NBIX. NBIX’s edge is concentrated in quality and value.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Value +1, not enough on its own to move the overall score.
New signals
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-14.7%)
Largest factor move: Momentum -1, not enough on its own to move the overall score.
New signals
- 52-Week Low Proximity — bearish, risk_regime, long horizon (0.0%)
NBIX's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — NBIX and OCUL both carry a full feed there.
The central trade-off
NBIX (Neurocrine Biosciences, Inc.): the stronger current systematic profile, led by quality and value.
OCUL (Ocular Therapeutix, Inc.): the counter-case, on analyst expectations — but at materially higher volatility, 75.1% against 55%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
NBIXNBIX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
NBIXNBIX on combined revenue and EPS growth.
Value
NBIXNBIX on the peer-relative Value factor, by 36 points.
Momentum
NBIXNBIX on the Momentum factor, by 36 points.
Lower downside
NBIXNBIX on Risk Resilience, by 33 points.
Analyst upside
OCULOCUL on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors NBIX, analyst targets favor OCUL. That disagreement is the most useful thing on this page.
| Measure | NBIX | OCUL | Note |
|---|---|---|---|
| Implied upside to target | +23.5% | +125.4% | OCUL has more room |
| Target dispersion | +19.8% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 29 | 12 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor NBIX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | NBIX | 74 vs 38 |
| Fundamentals | NBIX | revenue growth 17.1% vs -4.5%; EPS growth 42% vs -20%; TTM ROE 5.3% vs -21.5%; gross margin 97.8% vs 87.3%; operating margin 23.8% vs -6.8% |
| Valuation | NBIX | Value 77 vs 41 |
| Technicals | NBIX | Price vs 50-day 12.7% vs -22.3%; vs 200-day 12.4% vs -30.3% |
| Risk Resilience | NBIX | Risk Resilience 69 vs 36 |
| Analyst expectations | OCUL | Target upside 23.5% vs 125.4% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of NBIX and OCUL and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 36 points. (supports the conclusion holding)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on NBIX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13NBIX lead: Strengthening — the AIQ differential moved from 24 to 36 points over 30 sessions.
- Today
- NBIX +36
- 74 vs 38
- 7 sessions ago
- NBIX +30
- 71 vs 41
- 30 sessions ago
- NBIX +24
- 68 vs 44
- 90 sessions ago
- NBIX +27
- 74 vs 47
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 2 bearish / 1 neutral, conflicted
Only NBIX
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-14.7%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- RSI Bearish Divergence — bearish, momentum, medium horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
0 bullish / 4 bearish / 2 neutral
Only OCUL
- 52-Week Low Proximity — bearish, risk_regime, long horizon (0.0%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (7.28%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- Downtrend Structure Active — bearish, trend, long horizon
Both carry 2 more signals that do not separate them: Death Cross Active, ADX Trend Strengthening.
NBIX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.18%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.11%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1OCUL closes the Quality gap — currently 37 points behind, the largest single contributor to NBIX's edge.
- 2OCUL's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3NBIX's conflicting signal state resolves bearish — it currently carries 4 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
NBIX leads on balance| Metric | NBIX | OCUL |
|---|---|---|
| Revenue growth (YoY) | 17.1% | -4.5% |
| EPS growth (YoY) | 42% | -20% |
| Gross margin | 97.8% | 87.3% |
| Operating margin | 23.8% | -6.8% |
| Return on equity (TTM) | 5.3% | -21.5% |
| Debt to equity | 0.1 | 0.18 |
Performance
NBIX leads 6 of 6 windows| Metric | NBIX | OCUL |
|---|---|---|
| 1 week (5 sessions) | 1.7% | -5.8% |
| 1 month (20 sessions) | 23.4% | -9.6% |
| 3 months (63 sessions) | 8.4% | -41.7% |
| 6 months (126 sessions) | 5.7% | -32.2% |
| Year to date | 18% | -48.8% |
| 1 year (252 sessions) | 14% | -46% |
Technicals
NBIX has the stronger structure| Metric | NBIX | OCUL |
|---|---|---|
| RSI (14) | 64.4 | 37.6 |
| ADX (14) | 33.6 | 40.4 |
| Price vs 50-day | 12.7% | -22.3% |
| Price vs 200-day | 12.4% | -30.3% |
| Volatility (1M, annualized) | 55% | 75.1% |
Risk
NBIX is the more resilient| Metric | NBIX | OCUL |
|---|---|---|
| Beta | 0.7 | 1.39 |
| Sharpe ratio | 0.49 | -0.45 |
| Sortino ratio | 0.72 | -0.67 |
| Max drawdown | -27.2% | -61.5% |
| Current drawdown | -9.8% | -61.5% |
| Annualized volatility | 35.2% | 76.1% |
| Value at risk (95%) | -3.4% | -6.7% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, NBIX or OCUL?
On the Algovestiq AIQ Score, NBIX is the stronger of the two as of Nov 15, 2026, scoring 74 against OCUL's 38. The edge comes from quality and value. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is NBIX or OCUL the better buy right now?
NBIX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor NBIX over OCUL?
The composite weights Quality, Value, Momentum and Risk Resilience. NBIX leads Quality by 37 points; NBIX leads Value by 36 points; NBIX leads Momentum by 36 points. NBIX leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by OCUL simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.
Which has more analyst upside, NBIX or OCUL?
Analyst price targets imply +23.5% upside for NBIX and +125.4% for OCUL, so the Street currently favors OCUL. That points the opposite way to the AIQ Score, which favors NBIX. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, NBIX or OCUL?
NBIX is the better-valued of the two on the peer-relative Value factor. NBIX on the peer-relative Value factor, by 36 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, NBIX or OCUL?
NBIX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, NBIX or OCUL?
NBIX on the Momentum factor, by 36 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, NBIX or OCUL?
NBIX is the more resilient of the two, so the other name carries the higher downside risk. NBIX on Risk Resilience, by 33 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is NBIX more profitable than OCUL?
NBIX leads on the comparable margin measures — gross margin 97.8% vs 87.3%; operating margin 23.8% vs -6.8%; ttm roe 5.3% vs -21.5%.
Is NBIX's lead over OCUL getting stronger or weaker?
NBIX lead: Strengthening — the AIQ differential moved from 24 to 36 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the NBIX vs OCUL verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: OCUL closes the Quality gap — currently 37 points behind, the largest single contributor to NBIX's edge; OCUL's Death Cross Active resolves — a bearish trend rule currently active against it; NBIX's conflicting signal state resolves bearish — it currently carries 4 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about NBIX and OCUL?
NBIX: 4 bullish / 2 bearish / 1 neutral, conflicted. OCUL: 0 bullish / 4 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on NBIX is Death Cross Active (bearish, long horizon). On OCUL it is Death Cross Active (bearish, long horizon).
Compare NBIX and OCUL with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.